Supernus Pharmaceuticals Inc . (NASDAQ:SUPN) recently disclosed in an SEC filing that Sr. VP of IP and CSO, Bhatt Padmanabh P., engaged in transactions involving the company's common stock. According to the document, Bhatt executed a sale of 3,884 shares at prices ranging from $32.98 to $33.00, resulting in a total value of approximately $128,133.
The transactions took place on March 12, 2024, and were executed under a previously established 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for buying and selling stocks at a time when they are not in possession of nonpublic information. This plan had been adopted on September 7, 2023.
Additionally, on the same date, Bhatt acquired 3,884 shares of Supernus Pharmaceuticals at a price of $12.98 per share, amounting to a total of $50,414. The price reported for the sale represents a weighted average, suggesting that the shares were sold in multiple transactions within the stated price range.
Following these transactions, Bhatt's direct ownership in the company's common stock has changed, reflecting the new totals post-trade. The filing also noted that the options involved had vested in four equal annual installments beginning on March 1, 2017, and are set to expire on March 1, 2026.
Investors and followers of Supernus Pharmaceuticals may view such insider transactions as a normal part of executive compensation and portfolio management. The details of such trades are publicly disclosed to ensure transparency and to comply with SEC regulations.
InvestingPro Insights
Amidst recent insider trading activity, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) continues to exhibit financial metrics and market performance that may influence investor perception. With a market capitalization of approximately $1.83 billion, the company's position within the pharmaceutical industry is notable. An interesting aspect to consider is the company's strong liquidity position, as highlighted by an InvestingPro Tip that Supernus holds more cash than debt on its balance sheet, which can be a positive sign for investors looking for financially stable companies.
Moreover, Supernus has demonstrated a significant return over the past week, with a price total return of 12.5%. This short-term performance, coupled with a robust return over the last month at 25.76%, may indicate a bullish trend for the stock. However, it's worth noting that the company's P/E ratio stands at a high 1380, which suggests that the stock is trading at a premium relative to its earnings, a point that investors may need to consider, especially when compared to the adjusted P/E ratio for the last twelve months of Q4 2023 at 111.1.
For investors seeking further insights into Supernus Pharmaceuticals, there are additional InvestingPro Tips available that delve into aspects such as earnings growth expectations and analysts' revisions of earnings upwards for the upcoming period. To explore these insights and more, consider visiting InvestingPro, where a total of 13 tips are available to help inform your investment decisions. Plus, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.